ROIVANT SCIENCES LTD. Other Comprehensive Income (Loss), Net of Tax
ROIVANT SCIENCES LTD. (ROIV) reported Other Comprehensive Income (Loss), Net of Tax of -$3.44 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-06
- ROIVANT SCIENCES LTD. other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was -$3.44M, a 141.92% decline year-over-year.
- ROIVANT SCIENCES LTD. other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was -$18.05M, a 1951.38% decline year-over-year.
- ROIVANT SCIENCES LTD. other comprehensive income (loss), net of tax for the quarter ending 2025-12-31 was $942.00K, a 96.39% decline year-over-year.
- ROIVANT SCIENCES LTD. other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was $2.32M, a 1025.24% increase year-over-year.
- ROIVANT SCIENCES LTD. other comprehensive income (loss), net of tax for fiscal 2026 was -$6.58M, a 148.90% decline from fiscal 2025.
- ROIVANT SCIENCES LTD. other comprehensive income (loss), net of tax for fiscal 2025 was $13.46M.
- ROIVANT SCIENCES LTD. other comprehensive income (loss), net of tax for fiscal 2024 was -$936.00K.
- ROIVANT SCIENCES LTD. other comprehensive income (loss), net of tax for fiscal 2023 was -$1.49M.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.44M 10-Q · filed 2026-08-06 | -$21.49M derived: sum of 2 quarters · filed 2026-08-06 | -$20.55M derived: sum of 3 quarters · filed 2026-08-06 | -$18.23M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$18.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | -$17.11M derived: sum of 2 quarters · filed 2026-05-20 | -$14.79M derived: sum of 3 quarters · filed 2026-05-20 | -$6.58M 10-K · filed 2026-05-20 |
| 2025-12-31 | $942.00K 10-Q · filed 2026-02-06 | $3.26M derived: sum of 2 quarters · filed 2026-02-06 | $11.47M 10-Q · filed 2026-02-06 | $12.44M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-09-30 | $2.32M 10-Q · filed 2025-11-10 | $10.53M 10-Q · filed 2025-11-10 | $11.50M derived: sum of 3 quarters · filed 2026-08-06 | $37.61M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $8.21M 10-Q · filed 2026-08-06 | $9.18M derived: sum of 2 quarters · filed 2026-08-06 | $35.29M derived: sum of 3 quarters · filed 2026-08-06 | $35.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $975.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $27.09M derived: sum of 2 quarters · filed 2026-05-20 | $27.29M derived: sum of 3 quarters · filed 2026-05-20 | $13.46M 10-K · filed 2026-05-20 |
| 2024-12-31 | $26.11M 10-Q · filed 2026-02-06 | $26.32M derived: sum of 2 quarters · filed 2026-02-06 | $12.48M 10-Q · filed 2026-02-06 | $37.16M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-09-30 | $206.00K 10-Q · filed 2025-11-10 | -$13.63M 10-Q · filed 2025-11-10 | $11.05M derived: sum of 3 quarters · filed 2026-05-20 | -$14.02M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-06-30 | -$13.83M 10-Q · filed 2025-08-11 | $10.84M derived: sum of 2 quarters · filed 2026-05-20 | -$14.22M derived: sum of 3 quarters · filed 2026-05-20 | -$10.62M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-03-31 | $24.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | -$390.00K derived: sum of 2 quarters · filed 2026-05-20 | $3.21M derived: sum of 3 quarters · filed 2026-05-20 | -$936.00K 10-K · filed 2026-05-20 |
| 2023-12-31 | -$25.07M 10-Q · filed 2025-02-10 | -$21.46M derived: sum of 2 quarters · filed 2025-02-10 | -$25.61M 10-Q · filed 2025-02-10 | -$27.65M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-09-30 | $3.60M 10-Q · filed 2024-11-12 | -$546.00K 10-Q · filed 2024-11-12 | -$2.58M derived: sum of 3 quarters · filed 2025-05-29 | -$11.55M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-06-30 | -$4.15M 10-Q · filed 2024-08-09 | -$6.18M derived: sum of 2 quarters · filed 2025-05-29 | -$15.16M derived: sum of 3 quarters · filed 2025-05-29 | -$11.40M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-03-31 | -$2.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-29 | -$11.01M derived: sum of 2 quarters · filed 2025-05-29 | -$7.26M derived: sum of 3 quarters · filed 2025-05-29 | -$1.49M 10-K · filed 2025-05-29 |
| 2022-12-31 | -$8.97M 10-Q · filed 2024-02-13 | -$5.22M derived: sum of 2 quarters · filed 2024-02-13 | $547.00K 10-Q · filed 2024-02-13 | $563.00K derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-09-30 | $3.75M 10-Q · filed 2023-11-13 | $9.52M 10-Q · filed 2023-11-13 | $9.54M derived: sum of 3 quarters · filed 2023-11-13 | $7.14M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $5.77M 10-Q · filed 2023-08-14 | $5.78M derived: sum of 2 quarters · filed 2023-08-14 | $3.39M derived: sum of 3 quarters · filed 2023-08-14 | $5.93M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $16.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-28 | -$2.38M derived: sum of 2 quarters · filed 2023-06-28 | $168.00K derived: sum of 3 quarters · filed 2023-06-28 | -$2.27M 10-K · filed 2023-06-28 |
| 2021-12-31 | -$2.39M 10-Q · filed 2023-02-13 | $152.00K derived: sum of 2 quarters · filed 2023-02-13 | -$2.29M 10-Q · filed 2023-02-13 | $8.93M derived: sum of 4 quarters · filed 2023-02-13 |
| 2021-09-30 | $2.54M 10-Q · filed 2022-11-14 | $106.00K 10-Q · filed 2022-11-14 | $11.33M derived: sum of 3 quarters · filed 2022-11-14 | $5.79M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$2.44M 10-Q · filed 2022-08-15 | $8.78M derived: sum of 2 quarters · filed 2022-08-15 | $3.24M derived: sum of 3 quarters · filed 2022-08-15 | $2.21M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $11.22M derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-28 | $5.68M derived: sum of 2 quarters · filed 2022-06-28 | $4.65M derived: sum of 3 quarters · filed 2022-06-28 | $3.83M 10-K · filed 2022-06-28 |
| 2020-12-31 | -$5.54M 10-Q · filed 2022-02-14 | -$6.58M derived: sum of 2 quarters · filed 2022-02-14 | -$7.39M 10-Q · filed 2022-02-14 | |
| 2020-09-30 | -$1.03M 10-Q · filed 2021-11-15 | -$1.85M 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | -$820.00K 10-Q · filed 2021-09-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |